XML 73 R53.htm IDEA: XBRL DOCUMENT v3.19.1
Share-Based Payments - SOP 2015 (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Aug. 25, 2016
Sep. 23, 2015
Apr. 02, 2015
Additional disclosures            
Share-based compensation expense $ 5,154 $ 5,732 $ 2,545      
SOP 2015            
Weighted average exercise price in $ per share            
Outstanding balance at beginning of year (in dollars per share) $ 8.35 $ 7.83 $ 7.61      
Granted (in dollars per share)   9.02 8.02      
Exercised (in dollars per share)     7.21      
Forfeited (in dollars per share) 8.41 8.60 7.64      
Outstanding balance at end of year (in dollars per share) 8.34 8.35 7.83      
Vested and exercisable balance at end of year (in dollars per share) $ 8.10 $ 7.68 $ 7.52      
Options            
Outstanding at beginning of year (in shares) 3,044,899 1,794,360 1,092,300      
Granted (in shares)   1,458,300 922,130      
Exercised (in shares)     (23,360)      
Forfeited (in shares) (201,986) (207,761) (196,710)      
Outstanding at end of year (in shares) 2,842,913 3,044,899 1,794,360      
Vested and exercisable at end of year (in shares) 1,844,590 989,656 452,210      
Additional disclosures            
Total intrinsic value of options exercised     $ 181      
SOP 2015 | $4.06 per share to $11.00 per share            
Additional disclosures            
Options outstanding (in shares) 2,842,913          
Exercise price minimum range $ 4.06          
Exercise price maximum range $ 11.00          
Weighted average remaining contractual life 7 years 4 months 24 days          
SOP 2015 | Stock Options            
Share-Based Payments            
Vesting period 4 years          
Additional disclosures            
Share-based compensation expense $ 3,200 $ 5,600 $ 2,500      
Weighted-average grant date fair value (in dollars per share)   $ 5.05 $ 4.76      
Fair Value Assumptions            
Expected term of options (in years)   6 years 1 month 6 days 6 years      
Dividend yield (as a percent)   0.00% 0.00%      
Total unrecognized compensation related to unvested options $ 5,400          
Recognition period 2 years 1 month 6 days          
SOP 2015 | Stock Options | Minimum            
Fair Value Assumptions            
Expected volatility (as a percent)   55.60% 59.80%      
Risk-free interest rate (as a percent)   1.89% 1.15%      
Term of U.S. treasury securities used to estimate risk free interest rate   5 years 5 years      
SOP 2015 | Stock Options | Maximum            
Fair Value Assumptions            
Expected volatility (as a percent)   62.00% 67.20%      
Risk-free interest rate (as a percent)   2.10% 2.09%      
Term of U.S. treasury securities used to estimate risk free interest rate   7 years 7 years      
SOP 2015 | Stock Options | Vesting period, year one            
Share-Based Payments            
Percentage that vests during the period 25.00%          
SOP 2015 | Stock Options | Vesting period, years 2-4            
Share-Based Payments            
Percentage that vests during the period 75.00%          
Monthly vesting percentage 2.083%          
Nabriva Therapeutics AG ("Nabriva Austria") | Common Stock | SOP 2015            
Share-Based Payments            
Maximum number of shares authorized       346,235 177,499 95,000